Leipzig, Germany

David Kosel

This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Metriopharm Ag. Active years: 2019.

USPTO Granted Patents = 1 

% Patents Active = 100.0


 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: David Kosel: Innovator in Pharmaceutical Chemistry

Introduction

David Kosel is a notable inventor based in Leipzig, Germany. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on crystalline forms of pharmaceutical compounds.

Latest Patents

David Kosel holds a patent for the "Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said form." This invention relates to the provision of a new crystalline form for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium. It also covers the use of this form for medical purposes, methods for producing the crystalline form, and pharmaceutical preparations that include this form. He has 1 patent to his name.

Career Highlights

David Kosel is associated with Metriopharm AG, where he applies his expertise in pharmaceutical development. His work has been instrumental in advancing the understanding and application of pharmaceutical compounds.

Collaborations

Throughout his career, David has collaborated with notable professionals in the field, including Wolfgang Brysch and Josef Breu. These collaborations have contributed to the success of his projects and innovations.

Conclusion

David Kosel's contributions to pharmaceutical chemistry highlight his innovative spirit and dedication to improving medical treatments. His work continues to influence the field and pave the way for future advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…